A large proportion of human immunodeficiency virus (HIV)-infected individuals are also infected with human T-cell leukemia virus type I (HTLV-I) or HTLV-II (16) , cytomegalovirus (8, 30) , or human herpesvirus 6 (32) . Several studies suggest that those infected with a second virus have a more aggressive form of the disease than those infected with HIV alone (2, 13a, 43, 46) . It has been proposed that increased transcriptional activation of HIV by other viruses, such as herpesviruses (14, 22, 23) , papovaviruses (11), hepatitis B virus (33) , and HTLV (35) , may account for these findings. It is possible that, in addition to cross-transactivation, phenotypic mixing of HIV with other viruses plays a role in pathogenesis.
Mixing of envelope glycoproteins in doubly infected cells to form pseudotype virions has been demonstrated for several of the enveloped viruses (reviewed in reference 1). Recently it was reported that HIV produced in cells infected with xenotropic murine leukemia virus (MLV) (18) , amphotropic MLV (A-MLV) (6, 38) , or herpes simplex virus (51) has an expanded host range, suggesting that pseudotyped virions had formed. There is suggestive evidence of a role for pseudotypes in pathogenesis in the feline system, in which it has been shown that cats coinfected with feline immunodeficiency virus (FIV) and feline leukemia virus have a more aggressive immunodeficiency than those infected with FIV alone (26) . While the amount of feline leukemia virus present in the coinfected cats was not increased, FIV was found in nonlymphoid tissues, which are not normally targets of the virus.
The mechanism by which viruses incorporate homologous or heterologous envelope glycoproteins is poorly understood. Incorporation of the homologous envelope has been postulated to require interaction of the Gag matrix protein with the transmembrane domain of the envelope glycoprotein. This model is supported by the finding that pl9"'' of Rous sarcoma virus can be chemically cross-linked to * Corresponding author.
gp37ef"", indicating that the two proteins are in contact in the virion (10) . It is not clear, however, that this interaction drives incorporation of envelope glycoprotein molecules into the virion. In Rous sarcoma virus, the cytoplasmic tail of the transmembrane protein is not essential for envelope incorporation, as truncation of this segment did not decrease the infectivity or the amount of mutant envelope glycoprotein in the virions (27) .
Pseudotypes have previously been formed only in doubly infected cells that contain all the components of the two viruses. Thus, it has not been clear whether heterologous envelope glycoprotein incorporation depends on incorporation of the homologous envelope glycoprotein or, possibly, on incorporation of small amounts of the heterologous gag proteins. We have established methods for the generation of HIV type 1 (HIV-1) and HTLV-II pseudotype viruses that allowed us to test the ability of these viruses to incorporate heterologous envelope glycoproteins in the presence or absence of the homologous envelope glycoprotein and in the absence of other heterologous viral components. This approach also allowed us to study the role that the envelope glycoprotein plays in determining the host range and mode of transmission of HIV and HTLV.
HTLV-I PSEUDOTYPES OF HIV 163 restriction fragment containing the SV40 origin of replication and early-region promoter-enhancer linked to the neo gene (37) . The env deletion does not affect the tax-rex exons.
Construction of envelope glycoprotein expression vectors. The HIV envelope glycoprotein vector, SV-HIV-env, was constructed by ligating the SacI (nucleotides 5999 to 8896; 39) fragment of HIV HXB2 to SmaI-digested pSV7d. The HTLV-I envelope glycoprotein vector, SV-HTLV-I-env, was constructed by ligating a HindIII-PstI-cleaved fulllength HTLV-I env cDNA to similarly cleaved pSV7d. The Rev-responsive element of HIV (BglII-HindIII, positions 7620 to 8140) was placed in the 3' untranslated region of the env gene. A-MLV and ecotropic MLV (E-MLV) envelope glycoprotein vectors, SV-A-MLV-env and SV-E-MLV-env, were constructed by ligating the BglII-NheI fragment of Moloney MLV or A-MLV 4070a (nucleotides 5407 to 7846; 13) to BamHI-XbaI-digested pSV7d. The MLV long terminal repeat (LTR) (EcoRI-linkered EcoRI-HindIII fragment of T-Moloney MLV [20] ) was inserted at the EcoRI site between the SV40 enhancer-promoter and env genes of both plasmids.
Virus production. COS cells (1.2 x 106) were seeded in 10-cm-diameter dishes and transfected the next day with 15.0 ,ug of each plasmid plus, in some cases, 3.0 ,ug of pcRev by the calcium-phosphate-chloroquine procedure (42) . The precipitate was replaced by fresh medium after 12 h, and the cells were refed 24 and 48 h later. Virus was harvested 72 h after transfection, filtered through a 0.45-,um-pore-size membrane, and used without freezing.
Cell-free infection. Virus produced by the transfected COS cells (0.5, 0.1, and 0.01 ml) was incubated in a total volume of 0.5 ml with 2.0 x 105 cells in a 6-well culture dish. After 2 to 4 h, 0.5 ml of medium was added. Virus was removed after 12 h, and 2.0 ml of medium was added to each well. Two days after infection, 1/20 of the cells was transferred to mycophenolic acid selection medium (Dulbecco modified Eagle medium containing 10% dialyzed fetal calf serum, 250 ,ug of xanthine per ml, 14 ,ug of hypoxanthine per ml, 20 mM HEPES [N-2-hydroxyethylpiperazine-N' -2-ethanesulfonic acid; pH 7.0], and 50 ,g of mycophenolic acid [CalbiochemBehring, La Jolla, Calif.] per ml) or to neomycin selection medium (medium supplemented with 250 ,ug of G418 per ml). Cells were fed every 3 days, and after 10 to 12 days, colonies were stained with 0.2% crystal violet-25% isopropanol-5% acetic acid and counted. Colonies in the well containing the greatest number of discrete colonies were counted, normalized to 1.0 ml of virus, and multiplied by 5 to account for the 1:20 split and the approximately fourfold increase in cell number between the time of infection and selection.
Infection by cocultivation. COS cells were treated 48 h after transfection for 3 h with 10 ,ug of mitomycin C per ml. In plasmids SV-HIV-I-env and SV-HTLV-I-env, transcription is driven by the SV40 enhancer-promoter. In plasmids SV-A-MLV-env and SV-E-MLV-env, transcription is driven by the MLV LTR. In SV-HTLV-I-env, the Rev-responsive element (RRE) of HIV-1 was placed in the 3' untranslated region of a full-length HTLV-I env cDNA clone to allow transport of the mRNA to the cytoplasm in the presence of Rev. SV-A-MLV-env and SV-E-MLV-env contain the SV40 enhancer-promoter, the LTR of Moloney MLV, and the A-MLV (strain 4070a; 13) (19) . In the absence of Rev, HIV-1 and HTLV-I envelope glycoproteins were expressed at low or undetectable levels, respectively ( Fluorescence-activated cell sorter analysis showed that both envelope glycoproteins were present at the cell surface, although the level of gp46 was considerably lower than that of gpl60 (data not shown). Lysates of COS cells transfected with SV-E-MLV-env and SV-A-MLV-env contained bands corresponding to the precursor and processed forms of the MLV envelope glycoprotein gp7O (Fig. 2C, lanes 3 and 5) . These products comigrated with the envelope glycoproteins from control cells, producing wild-type E-or A-MLV (Fig. 2C,  lanes 2 and 4) .
HIV(MLV) and HIV(HTLV) pseudotypes have altered cell tropisms and host ranges. To test the ability of HIV-1 to form pseudotypes with heterologous envelope glycoproteins, COS cells were cotransfected with the envelope expression vectors and the HIV-1 vector HIV-gpt. The resulting viruses were tested for infectivity on human and murine cell lines using cell-free and cocultivation protocols (as described in Materials and Methods). Virus produced by COS cells transfected with HIV-gpt in the absence of envelope glycoprotein showed an undetectable (NIH 3T3 and HeLa) or a very low (HOS and HeLa-T4) level of infection in cell-free and cocultivation assays (Table 1) . Virus produced by COS cells cotransfected with HIV-gpt and the gpl60 vector SV-HIV-I-env displayed the expected host range for HIV, efficiently infecting only CD4+ human cells (HeLa-T4) by either cell-free or cocultivation routes (Table 1) . Virus produced by COS cells cotransfected with HIV-gpt and A-MLV or E-MLV env vectors had the host range characteristic not of HIV, but of the virus from which the envelope glycoprotein was derived: HIV(E-MLV) infected only murine cells (3T3), and HIV(A-MLV) infected both human and murine cells (HeLa, HeLa-T4, HOS, and 3T3). These pseudotypes were infectious by cell-free infection and cocultivation (Table 1) . HIV pseudotyped by the HTLV-I envelope glycoprotein infected CD4-and CD4+ human cells and inefficiently infected 3T3 cells, which is consistent with previous reports of low levels of HTLV receptor on murine cells (36) . Interestingly, the titer of HIV(A-MLV) in cell-free infection was considerably higher on HeLa-T4 cells than that of HIV bearing the homologous envelope glycoprotein gpl60. This difference in titer is probably not due to a difference in expression level of the two envelope glycoproteins, because by immunoblotting, the protein levels appear similar (Fig. 2) . While this interpretation assumes similar sensitivity of the two antibodies in detecting envelope glycoprotein, it is supported by the finding that two other antibodies gave similar results (data not shown). The significance of this finding is discussed below.
Pseudotypes bearing the HTLV-I envelope glycoprotein are [49] ). To examine these possibilities, COS cells were cotransfected with a mixture of HIV-gpt, SV-HIV-I-env, and either SV-E-MLV-env or SV-HTLV-I-env, and the viruses produced were assayed by cocultivation. Both HIV(E-MLV) and HIV(HTLV-I) pseudotype formation appeared unaffected by the presence of the HIV-1 envelope glycoprotein (Table 1 ). In addition, in the case of the E-MLV-env-HIV-I-env mixture, the titer on HeLa-T4 was similar to that of HIV bearing the HIV-1 envelope glycoprotein alone. Therefore, it can be concluded that the HIV-1 envelope glycoprotein was not detectably inhibited from being incorporated into the virion by the presence of the heterologous envelope glycoprotein. It is unclear, however, whether these virions consisted of a single population containing both envelope glycoproteins or two populations, each with a single envelope glycoprotein. However, pseudotypes produced in other systems have been shown to consist of mixed envelope-containing virions (44, 45, 49) .
Pseudotyping of HTLV permits more efficient cell-free transmission. Previous reports have noted the inability of HTLV-I and -II to be transmitted by cell-free virus preparations (5, 50) . Cell-free transmission was achieved in one study, but this could have been a very low-efficiency event (7) . The observation that HIV(HTLV-I) pseudotypes were more efficiently transmitted via cocultivation than as cellfree virions suggested that the HTLV envelope glycoprotein may be responsible for this preference. To test this hypothesis, we prepared reciprocal pseudotypes using the HTLV-II retrovirus vector. SV-HTLV-II-neo was cotransfected with the HTLV-I E-MLV and A-MLV envelope glycoprotein vectors, and the resulting viruses were tested by cocultivation and cell-free infection of human and murine cells ( Table  2 ). The titers produced with the HTLV-II vector were considerably lower than those produced with the HIV vector. This may be because of the previously described weak transcriptional activity of the HTLV LTR in nonlymphoid cells such as the COS cells used in our work (4) . As expected, cotransfection of the HTLV-I env vector with SV-HTLV-II-neo resulted in virus that infected HIOS cells by cocultivation but not by cell-free infection. In contrast, cotransfection of A-or E-MLV env vectors resulted in virus that readily infected cells by cell-free infection and cocultivation and showed the appropriate host range [HOS and 3T3 for HTLV(A-MLV) and 3T3 for HTLV(E-MLV)]. From these results we conclude that HTLV-I1 can be pseudotyped by MLV envelope glycoproteins and that the low infectivity of cell-free HTLV-Il virions can be overcome by exchanging the glycoprotein.
DISCUSSION
The results of this study demonstrate that HIV-1 can be readily pseudotyped by the envelope glycoprotein of HTLV-I, resulting in expanded cell tropism and host range. In addition, HIV-1 can be pseudotyped by the E-MLV envelope glycoprotein and, in agreement with recent reports (38) , by the A-MLV envelope glycoprotein. Similarly, we show here that HTLV-IT can be pseudotyped by the A-and E-MLV envelope glycoproteins. Each pseudotype displayed the tropism characteristic of the heterologous envelope glycoprotein it had incorporated. These pseudotypes differ from those recently reported and from those produced by double infections in other viral systems in that these were produced in the absence of the homologous envelope glycoprotein and therefore contain pure rather than mixed envelopes. This fact enabled us to make several observations about the mechanisms by which pseudotypes are formed.
The mechanisms that control the incorporation of envelope glycoproteins into virions are not well understood. Envelope glycoproteins appear to be specifically incorpo-rated, since nearly all other cell membrane proteins are excluded from the viral envelope (3, 17, 31) . It has been suggested, in the case of rhabdovirus pseudotypes, that heterologous envelope glycoproteins are incorporated into the assembling virion by associating on the cell surface with homologous envelope glycoprotein molecules. The homologous envelope glycoprotein could then serve to nucleate the budding reaction (49) . In those pseudotypes, the heterologous envelope glycoprotein does not substitute for the homologous glycoprotein but instead is believed to occupy interstices between the homologous envelope glycoprotein molecules (21) . In that case, the ability of the heterologous envelope glycoprotein to be incorporated into the virion could be due to its ability to associate with the homologous glycoprotein. In contrast, the pseudotypes produced in our experiments were formed in the absence of the homologous envelope glycoprotein. Furthermore, the presence of the homologous envelope glycoprotein failed to enhance pseudotype formation. Our results are more consistent with a model of envelope glycoprotein incorporation in which some feature common to many envelope glycoproteins, such as a protein structural motif or the ability to form a two-dimensional array of envelope glycoprotein molecules on the cell membrane, is recognized by the assembling core particle. An alternative model that cannot be ruled out by our results is that envelope and core components may be targeted to a specific region of the cell membrane from which most cellular proteins are excluded, thereby allowing the formation of virions containing only the virion-encoded components. This model seems unlikely, however, because virions appear to bud at random positions from the cell surface.
While it is thought that phenotypic mixing does not involve extensive mixing of virion proteins other than the envelope glycoprotein (44, 45) , it is possible that pseudotyping requires the incorporation of small amounts of heterologous Gag that serves to stimulate the incorporation of heterologous envelope glycoprotein molecules into the virion. Our results indicate that this is unlikely to be the case, because heterologous Gag was absent during the assembly of these pseudotypes.
The titers of HIV(MLV) were higher than those of HIV-1 bearing the homologous envelope glycoprotein, suggesting that the envelope glycoproteins of MLV function more effectively than gpl60. This could be the result of the inefficient processing and transport to the cell surface that has been observed for gp160, the majority of which is targeted to lysosomes for degradation (48) . In addition, because gpl20 is not covalently linked to gp4l, it may be easily removed from virions. Thus, pseudotyping of HIV-1 can increase its infectivity as well as broaden its host range.
Similarly, pseudotyping of HTLV-II increases the infectivity of the virions produced. In this case, the incorporation of a MLV envelope glycoprotein considerably increased the infectivity of cell-free virions. One explanation for these results is that the HTLV-I envelope glycoprotein is unstable and largely inactive in cell-free preparations of virus. Cocultivation would allow the virus to spread more efficiently because it is exposed to target cells shortly after budding. Pseudotyping in an infected individual could give rise to virions capable of being transmitted without the need for cell-cell contact. Such particles might therefore infect tissues not normally accessible to the virus.
In the course of these studies we have developed vectors useful for the study of HTLV. HTLV has been difficult to study because of its slow growth and poor transmissibility. By using SV-HTLV-II-neo, it is possible to rapidly produce virus and quantitate its infectivity (but not its replication, because of its env deletion). In addition, the biohazard associated with these virions is expected to be much lower than that of replication-competent virus.
Pseudotyping has not yet been demonstrated in individuals infected with HIV and another virus. However, it is likely that doubly infected cells are present in individuals infected with HIV and HTLV, since both viruses are lymphotropic. Viruses produced by such cells would be capable of infecting tissues not normally infectable with HIV. Phenotypic mixing of HIV with HTLV, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6, or other viruses frequently found in HIV-infected individuals could account for the spread of the virus to CD4-cells. HIV can be found in the CD4+ macrophages of the brain but has also been reported to be present in CD4-astrocytic, neuronal, and endothelial cells (9, 29, 47) . Infection of cultured cells of neural lineage has been reported to occur by a CD4-independent mechanism (12, 15) that could involve recognition by gpl60 of a non-CD4 cell surface molecule or could be due to the presence of HIV pseudotypes arising in cells producing a second virus. Such pseudotypes may have an important role in the pathogenesis of HIV-related syndromes, such as those involving the central nervous system.
